• share
• favorite_border

During a virtual commencement ceremony on Wednesday, May 19, 2021, at 3:00 PM ET, Memorial Sloan Kettering Cancer Center (MSK) will recognize seven Gerstner Sloan Kettering (GSK) 2021 graduates and honor Joan Argetsinger Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry at Yale School of Medicine and a Howard Hughes Medical Institute Investigator, with the 2021 Honorary Degree and the Memorial Sloan Kettering Medal for Outstanding Contributions to Biomedical Research.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) today announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of new therapies to treat this disease.

• share
• favorite_border

During a virtual awards ceremony today, Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation recognized eight distinguished MSK staff members and one team for their exemplary service. Each member was honored with the 2021 Robbins Family Award for Nursing Excellence. The virtual awards ceremony took place today, Monday, May 12, at 8:30 AM ET, to commemorate National Nurses Week (May 6–12).

• share
• favorite_border

During a virtual awards ceremony today, Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation recognized eight distinguished MSK staff members and one team for their exemplary service. Each member was honored with the 2021 Robbins Family Award for Nursing Excellence. The virtual awards ceremony took place today, Monday, May 12, at 8:30 AM ET, to commemorate National Nurses Week (May 6–12).

• share
• favorite_border

Research Presented Found that Copanlisib-Rituximab Combination Reduced Lymphoma Progression or Death by Nearly Half in CHRONOS-3 Trial

• share
• favorite_border

New York City's Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments for March 2021.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announced that Sloan Kettering Institute (SKI) researchers Regina Bou Puerto and Mijin Kim, PhD, have been named 2021 Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grant recipients. The Kravis WiSE initiative, created in 2020, provides sustained funding for scientific trainees as well as mentoring and significant professional development for women pursuing careers in biomedical research at MSK. The Kravis WiSE Symposium is held every year during Women’s History Month in March. This event hosts scientific leaders from MSK and other institutions.

• share
• favorite_border

New York City's Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments for February 2021.

• share
• favorite_border

The new positions reflect MSK’s commitment to expanding patient access to cancer care and supporting ongoing research aimed at reducing cancer disparities that stem from racial, ethnic, cultural, or socioeconomic barriers.

• share
• favorite_border

Early detection helps improve patient outcomes, but data shows that many cancers are going undiagnosed or untreated because of COVID-19.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces recent awards and appointments.

• share
• favorite_border

Memorial Sloan Kettering attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

• share
• favorite_border

Four MSK researchers out of 15 winners nationwide were named recipients of the prestigious award. They will each receive a grant of up to $600,000 per year for seven years to support their research in cancer.

• share
• favorite_border

Neuro-oncologist and renowned physician-scientist Ingo Mellinghoff will lead MSK’s distinguished Department of Neurology after previously serving as Acting Co-Chair.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

• share
• favorite_border

Computational biologist Thomas Norman, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will receive $1.5 million in direct costs upfront in the first year of a five-year award.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since U.S. News & World Report established the prestigious rankings more than 30 years ago, MSK has earned either the first or second spot for best cancer care in the country each year.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

• share
• favorite_border

A team of researchers at Memorial Sloan Kettering Cancer Center (MSK) reported on the epidemiology of COVID-19 illness experienced at an NCI-designated cancer center during the height of pandemic in New York City.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.

• share
• favorite_border

On Thursday, June 18, at 6:00 p.m. E.T. with an encore at 9:00 p.m., Memorial Sloan Kettering Cancer Center (MSK) will stream a special performance on visibleink.vimeo.mskcc.org, highlighting poignant and humorous perspectives On Cancer and Coronavirus, featuring works from its writing program, Visible Ink. This will be the 12th annual performance of stories written by MSK patients, and the first presented virtually. Visible Ink has always worked with many participants remotely, so it was well positioned to continue to connect MSK patients with experienced writers to support their written expression.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

• share
• favorite_border

The Memorial Sloan Kettering – Hackensack Meridian Health Partnership has formed an Immunology Research Collaboration, through which researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer. Three researchers' projects were selected in 2020 for funding support.

• share
• favorite_border

As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now – as the long-term toll of missed diagnoses and delayed treatments could be devastating for patients and their loved ones across the region and the country.

• share
• favorite_border

New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) revealed the effects of Medicaid expansion on cancer death rates on a national scale. The landmark study found that states that adopted Medicaid expansion following the passage of the Affordable Care Act (ACA) in 2010 saw greater decreases in cancer mortality rates than states that did not. The findings were presented as part of the press program for this year’s virtual annual meeting of the American Society of Clinical Oncology (ASCO).

• share
• favorite_border

Researches from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) found that children with cancer are not at a higher risk of being affected by COVID-19.

• share
• favorite_border

As we celebrate National Nurses Week, Memorial Sloan Kettering Cancer Center (MSK) and The Robbins Family Foundation recognize seven distinguished nursing staff members for their exemplary service. Each member of this select group is being honored with the inaugural 2020 Robbins Family Award for Nursing Excellence.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

• share
• favorite_border

Two researchers at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI) have been elected to the National Academy of Sciences (NAS). Scott Keeney, PhD, a molecular biologist, and Christopher Lima, PhD, a structural biologist, join more than a dozen MSK investigators who are already NAS members. SKI is the research enterprise of MSK, the world’s oldest and largest private cancer center. Members are elected in recognition of their distinguished and continuing achievements in original research. Membership is one of the highest honors bestowed upon scientists worldwide.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

• share
• favorite_border

To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center has appointed Roxanne Taylor as Chief Marketing and Communications Officer, effective February 3. In this role, Ms. Taylor will be responsible for shaping and enhancing the MSK brand and will be accountable for building the long-term equity of the brand with all stakeholders.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot building is the institution’s — and the city’s — largest freestanding cancer care facility. The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is a healing community dedicated to patient-centered care, made possible by a landmark donation and a pioneering vision that signifies a new era of cancer care.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) today announced that Claus Torp Jensen, PhD, has joined the institution as its first Chief Digital Officer and Head of Technology. His recruitment follows an expansive national search to identify a leader with the vision and experience to lead MSK’s digital transformation.

• share
• favorite_border

Today, researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) published results that examine elevated levels of a protein called prohibitin in the urine and tumors of children with Wilms’ tumors. Their findings could help doctors identify children who are at risk for disease recurrence and precisely tailor treatment to overcome drug resistance.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care. In addition to its ranking for overall cancer care, MSK was ranked #1 in Gynecology.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status.

• share
• favorite_border

Memorial Sloan Kettering Cancer Center (MSK) announced that the New York State Department of Health has issued an approval for a new molecular assay called Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).

• share
• favorite_border

LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food and Drug Administration expanded access program were presented by David Hyman, MD, the Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK), at the American Association for Cancer Research (AACR) Annual Meeting 2019. This research is featured in the meeting’s press program, and findings are being presented in the “Next Generation of Clinical Trials in Molecularly Driven Therapy” minisymposium.

• share
• favorite_border

During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness.

• share
• favorite_border

Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower gut microbiota diversity before having a transplant appear to be at higher risk for developing complications. These findings further support evidence that the connection between microbiota and outcomes starts before people begin the transplantation process. These findings were presented as part of the 2018 annual meeting of the American Society of Hematology (ASH) press program.

• share
• favorite_border

MSK experts in CAR-T therapy, immunotherapy, leukemia, lymphoma, blood and marrow stem cell transplantation, and more, are also available to comment on meeting news.

• share
• favorite_border

A randomized clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has shown that fecal microbiota transplants (FMTs)

• share
• favorite_border

Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.

• share
• favorite_border

Peter T. Meinke, PhD, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute.

• share
• favorite_border

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.

• share
• favorite_border

Researchers at Memorial Sloan Kettering (MSK) report that firefighters at the World Trade Center (WTC) scene in September 2001 were nearly twice as likely as the general population to have a multiple myeloma precursor condition called monoclonal gammopathy of undetermined significance (MGUS).